Cargando…

Investigation of the transforming growth factor-beta 1 signalling pathway as a possible link between hyperphosphataemia and renal fibrosis in feline chronic kidney disease

Chronic kidney disease (CKD) is common in geriatric cats, and is characterised in the majority of cases by tubulointerstitial inflammation and fibrosis. Hyperphosphataemia is a frequent complication of CKD and is independently associated with severity of renal fibrosis and disease progression. Trans...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lawson, J.S., Syme, H.M., Wheeler-Jones, C.P.D., Elliott, J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Balliere Tindall 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7814380/ https://www.ncbi.nlm.nih.gov/pubmed/33375963 http://dx.doi.org/10.1016/j.tvjl.2020.105582

Ejemplares similares

Urinary active transforming growth factor β in feline chronic kidney disease
por: Lawson, J.S., et al.
Publicado: (2016)

Characterisation of Crandell-Rees Feline Kidney (CRFK) cells as mesenchymal in phenotype
por: Lawson, J.S., et al.
Publicado: (2019)

Characterisation of feline renal cortical fibroblast cultures and their transcriptional response to transforming growth factor β1
por: Lawson, J. S., et al.
Publicado: (2018)

The cat as a naturally occurring model of renal interstitial fibrosis: Characterisation of primary feline proximal tubular epithelial cells and comparative pro-fibrotic effects of TGF-β1
por: Lawson, Jack S., et al.
Publicado: (2018)

Management of hyperphosphataemia in chronic kidney disease—challenges and solutions
por: Ketteler, Markus, et al.
Publicado: (2013)

Tailored synbiotic powder (functional food) to prevent hyperphosphataemia (kidney disorder)
por: Anand, Ajeeta, et al.
Publicado: (2021)

Plant-based dietary approach to stage 3 chronic kidney disease with hyperphosphataemia
por: Campbell, Thomas M, et al.
Publicado: (2019)

Symptomatic Hyperphosphataemia Following Phosphate Enema in A Healthy Adult
por: Carl, Ian, et al.
Publicado: (2007)

Considerations about the effectiveness and cost effectiveness of therapies in the treatment of hyperphosphataemia
por: Plagemann, Thomas, et al.
Publicado: (2011)

Author Correction: Tailored synbiotic powder (functional food) to prevent hyperphosphataemia (kidney disorder)
por: Anand, Ajeeta, et al.
Publicado: (2021)

Real-world management of hyperphosphataemia with sucroferric oxyhydroxide: the VELREAL multicentre study
por: Navarro-González, Juan F, et al.
Publicado: (2021)

Axl Tyrosine Kinase Protects against Tubulo-Interstitial Apoptosis and Progression of Renal Failure in a Murine Model of Chronic Kidney Disease and Hyperphosphataemia
por: Hyde, Gareth D., et al.
Publicado: (2014)

Aldosterone and the mineralocorticoid receptor in renal injury: A potential therapeutic target in feline chronic kidney disease
por: Spencer, Sarah, et al.
Publicado: (2020)

Complete heart block in a boy with hyperostosis–hyperphosphataemia syndrome: a case report
por: Hosseini, Zahra, et al.
Publicado: (2019)

Renal Senescence, Telomere Shortening and Nitrosative Stress in Feline Chronic Kidney Disease
por: Quimby, Jessica, et al.
Publicado: (2021)

Effect on Renal Function of Restoration of Euthyroidism in Hyperthyroid Cats with Iatrogenic Hypothyroidism
por: Williams, T.L., et al.
Publicado: (2014)

Profibrotic effects of angiotensin II and transforming growth factor beta on feline kidney epithelial cells
por: van Beusekom, Cyrina D, et al.
Publicado: (2018)

Urinary extracellular vesicles as a source of protein‐based biomarkers in feline chronic kidney disease and hypertension
por: Lawson, J. S., et al.
Publicado: (2022)

Feline Morbillivirus, a New Paramyxovirus Possibly Associated with Feline Kidney Disease
por: Choi, Eun Jin, et al.
Publicado: (2020)

Randomised clinical trial of ferric citrate hydrate on anaemia management in haemodialysis patients with hyperphosphataemia: ASTRIO study
por: Yokoyama, Keitaro, et al.
Publicado: (2019)

ICU-Admission Hyperphosphataemia Is Related to Shock and Tissue Damage, Indicating Injury Severity and Mortality in Polytrauma Patients
por: Rugg, Christopher, et al.
Publicado: (2021)

Elderly-onset calcinosis of hyperphosphataemic familial tumoural calcinosis/hyperostosis-hyperphosphataemia syndrome: the role of comorbid scleroderma
por: Iwasaki, Hiroaki
Publicado: (2023)

Risk Factors for Development of Chronic Kidney Disease in Cats
por: Finch, N.C., et al.
Publicado: (2016)

Severe hypocalcaemia and hyperphosphataemia caused by oral sodium phosphate fleet solution in a haemodialysis patient after parathyroidectomy
por: Mok, Maggie Ming Yee, et al.
Publicado: (2011)

Real-world safety and effectiveness of sucroferric oxyhydroxide for treatment of hyperphosphataemia in dialysis patients: a prospective observational study
por: Vervloet, Marc G, et al.
Publicado: (2021)

Plasma N‐Terminal Probrain Natriuretic Peptide, Vascular Endothelial Growth Factor, and Cardiac Troponin I as Novel Biomarkers of Hypertensive Disease and Target Organ Damage in Cats
por: Bijsmans, E.S., et al.
Publicado: (2017)

Relationship between Plasma Fibroblast Growth Factor‐23 Concentration and Survival Time in Cats with Chronic Kidney Disease
por: Geddes, R.F., et al.
Publicado: (2015)

Transforming growth factor-beta: possible roles in carcinogenesis.
por: Roberts, A. B., et al.
Publicado: (1988)

The effects of colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphataemia: a 1-year prospective randomized study
por: Locatelli, Francesco, et al.
Publicado: (2014)

Serum Cystatin C Concentrations in Cats with Hyperthyroidism and Chronic Kidney Disease
por: Williams, T.L., et al.
Publicado: (2016)

Cost Effectiveness of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in the Treatment of Hyperphosphataemia in Patients Receiving Dialysis, from the Perspective of the National Health Service in Scotland
por: Gutzwiller, Florian S., et al.
Publicado: (2015)

Modified-release nicotinamide for the treatment of hyperphosphataemia in haemodialysis patients: 52-week efficacy and safety results of the phase 3 randomized controlled NOPHOS trial
por: Ketteler, Markus, et al.
Publicado: (2022)

Plasma Renin Activity and Aldosterone Concentrations in Hypertensive Cats with and without Azotemia and in Response to Treatment with Amlodipine Besylate
por: Jepson, R.E., et al.
Publicado: (2013)

Changes in Systolic Blood Pressure over Time in Healthy Cats and Cats with Chronic Kidney Disease
por: Bijsmans, E.S., et al.
Publicado: (2015)

Possible Antiviral Activity of 5-Aminolevulinic Acid in Feline Infectious Peritonitis Virus (Feline Coronavirus) Infection
por: Takano, Tomomi, et al.
Publicado: (2021)

Psychometric Validation of a General Health Quality of Life Tool for Cats Used to Compare Healthy Cats and Cats with Chronic Kidney Disease
por: Bijsmans, E.S., et al.
Publicado: (2016)

Influence of chylomicron remnants on human monocyte activation in vitro
por: Bentley, C., et al.
Publicado: (2011)

In vitro and in vivo association of transforming growth factor-beta 1 with hepatic fibrosis
Publicado: (1989)

Thirty‐two cats with effusive or non‐effusive feline infectious peritonitis treated with a combination of remdesivir and GS‐441524
por: Green, Jodie, et al.
Publicado: (2023)

Efficacy and safety of PT20, an iron-based phosphate binder, for the treatment of hyperphosphataemia: a randomized, double-blind, placebo-controlled, dose-ranging, Phase IIb study in patients with haemodialysis-dependent chronic kidney disease
por: Sampson, Mark, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pu3spl06q6j4lr8b85obptkpl5